Aspect Partners’s Pacira BioSciences PCRX Stock Holding History

Aspect Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-48	Closed	-$1.19K	–	649
2025 Q1	$1.19K	Buy	+48	New	+$1.15K	﹤0.01%	489

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Aspect Partners's PCRX Position: Q2 2025 in Review

Aspect Partners sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 48 shares — an estimated $1.19K sold.

Aspect Partners first reported a position in PCRX in Q1 2025 and held it in 1 quarter. The position peaked at $1.19K in Q1 2025. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

Aspect Partners reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
Aspect Partners sold 48 Pacira BioSciences shares in Q2 2025, an estimated $1.19K.
Aspect Partners first reported a position in Pacira BioSciences in Q1 2025 and held it in 1 quarter.
Aspect Partners's Pacira BioSciences position peaked at $1.19K in Q1 2025.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on Aspect Partners's 13F filing for Q2 2025, filed 6 Aug 2025.